These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 25832853)

  • 1. Current and future treatment options for polycythemia vera.
    Griesshammer M; Gisslinger H; Mesa R
    Ann Hematol; 2015 Jun; 94(6):901-10. PubMed ID: 25832853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera.
    Reiter A; Harrison C
    Curr Hematol Malig Rep; 2016 Oct; 11(5):356-67. PubMed ID: 26894383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diagnosis and therapy of polycythemia vera in the era of JAK2].
    Lengfelder E
    Dtsch Med Wochenschr; 2013 Feb; 138(7):331-6. PubMed ID: 23393003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2019 Jan; 94(1):133-143. PubMed ID: 30281843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
    Tefferi A; Barbui T
    Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Therapeutic Approaches in Polycythemia Vera.
    Falchi L; Newberry KJ; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl(0):S27-33. PubMed ID: 26297275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A
    Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2020 Dec; 95(12):1599-1613. PubMed ID: 32974939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging drugs for polycythemia vera.
    Tibes R; Mesa RA
    Expert Opin Emerg Drugs; 2013 Sep; 18(3):393-404. PubMed ID: 23968379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polycythemia vera: current pharmacotherapy and future directions.
    Hensley B; Geyer H; Mesa R
    Expert Opin Pharmacother; 2013 Apr; 14(5):609-17. PubMed ID: 23480062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG.
    Michiels JJ; Barbui T; Finazzi G; Fuchtman SM; Kutti J; Rain JD; Silver RT; Tefferi A; Thiele J
    Leuk Lymphoma; 2000 Jan; 36(3-4):239-53. PubMed ID: 10674896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recent advances in polycythemia vera treatment].
    Edahiro Y
    Rinsho Ketsueki; 2020; 61(9):1187-1194. PubMed ID: 33162515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F.
    Stein BL; Oh ST; Berenzon D; Hobbs GS; Kremyanskaya M; Rampal RK; Abboud CN; Adler K; Heaney ML; Jabbour EJ; Komrokji RS; Moliterno AR; Ritchie EK; Rice L; Mascarenhas J; Hoffman R
    J Clin Oncol; 2015 Nov; 33(33):3953-60. PubMed ID: 26324368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polycythemia vera.
    Landolfi R; Nicolazzi MA; Porfidia A; Di Gennaro L
    Intern Emerg Med; 2010 Oct; 5(5):375-84. PubMed ID: 20237866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment strategies for low-risk polycythemia vera].
    Ota S
    Rinsho Ketsueki; 2024; 65(8):810-818. PubMed ID: 39231712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea.
    Sever M; Newberry KJ; Verstovsek S
    Leuk Lymphoma; 2014 Dec; 55(12):2685-90. PubMed ID: 24524340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polycythemia vera: aspects of its current diagnosis and initial treatment.
    Silver RT; Abu-Zeinah G
    Expert Rev Hematol; 2023 Apr; 16(4):253-266. PubMed ID: 37013802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [CME: Polycythemia vera].
    Wellauer Atencio M; Goede JS
    Praxis (Bern 1994); 2019 Sep; 108(13):835-842. PubMed ID: 31571535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Front-line therapy in polycythemia vera and essential thrombocythemia.
    Barbui T; Finazzi MC; Finazzi G
    Blood Rev; 2012 Sep; 26(5):205-11. PubMed ID: 22784966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.